Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

7 treatments under study, led by Allogeneic Lmp1lmp2specific Cytotoxic Tlymphocytes

Research Leaders

5 sponsors active, led by National Cancer Institute (NCI)

Related Conditions

Often studied with 7 related conditions

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 25/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

2Total
Phase 1 (1)
Phase 2 (1)

Trial Status

Recruiting1
Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT06672705Phase 1Recruiting

Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders

NCT02900976Phase 2CompletedPrimary

Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder

Showing all 2 trials

Research Network

Common Treatments

  • Allogeneic Lmp1lmp2specific Cytotoxic Tlymphocytes1
  • Biopsy1
  • Biospecimen Collection1
  • Computed Tomography1
  • Epcoritamab1

Active Sponsors

  • National Cancer Institute (NCI)2
  • Children's Oncology Group1
  • Timothy Voorhees1
  • Genmab1
  • AbbVie1

Top Investigators

Related Conditions

  • Recurrent Polymorphic Posttransplant Lymphoproliferative Disorder2
  • Refractory Polymorphic Posttransplant Lymphoproliferative Disorder2
  • Recurrent Monomorphic Posttransplant Lymphoproliferative Disorder2
  • Refractory Monomorphic Posttransplant Lymphoproliferative Disorder2
  • Monomorphic Posttransplant Lymphoproliferative Disorder1

Activity Timeline